1. Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome. (26th March 2019) Authors: Engel, S; Luessi, F; Henning, B; Bittner, S; Loquai, C; Zipp, F Journal: Annals of oncology Issue: Volume 30:Number 6(2019) Page Start: 1014 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗